Biosimilar antibodies are research-grade antibodies that are highly similar in structure, function and sequences to the approved original therapeutic antibodies. They are produced through recombination technology and have the same variable regions from the corresponding therapeutic antibodies, which making them reliable and more cost-effective research tools and alternative reagents in drug development and basic research.
CUSABIO has successfully expressed and validated many research-grade biosimilar antibodies, covering a variety of popular targets. All these research-grade biosimilar antibodies can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.
Our biosimilar antibodies are recombinantly expressed in mammalian cells with unmodified variable and Fc regions identical to the approved therapeutic antibodies.
We offer over 200 ready-to-use biosimilar antibodies covering key targets, including immune checkpoints, tumor drivers, and neurological markers.
Each batch is ELISA-validated for strong target binding and comes with an EC50 value for reliable performance.
We offer stable supply of research-grade biosimilar antibodies from ul to g level, proving multiple options to customers.
Serve as highly similar research tools for in vitro assessment of biological activities such as cytotoxicity and blocking effects of antibody drugs, enabling in-depth investigation into their mechanisms of action.
Used as critical reference standards or surrogate materials in the development of pharmacokinetic (PK) and immunogenicity (ADA) assays, facilitating method validation and bioequivalence evaluation.
Function as reliable positive controls in Flow Cytometry, IHC, and other detection platforms, or are utilized in the development of companion diagnostics to ensure assay specificity and accuracy.
With formulations suitable for in vivo administration, they can be directly applied in animal models for efficacy assessment and dose exploration, providing a foundation for preclinical research.
| Code | Product Name | Clone | Isotype |
|---|---|---|---|
| CSB-RA618774MA1HU | ADAM9 (izeltabart) Recombinant Monoclonal Antibody | izeltabart | hIgG1 |
| CSB-RA004888MA3HU | CD19 (FMC63) Recombinant Monoclonal Antibody | FMC63 | hIgG1 |
| CSB-RA004888MA4HU | CD19 (Tafasitamab) Recombinant Monoclonal Antibody | Tafasitamab | hIgG1 |
| CSB-RA872550MA1HU | GP6 (glenzocimab) Recombinant Monoclonal Antibody | glenzocimab | hIgG1 |
| CSB-RA007403MA3HU | EDNRA (Getagozumab) Recombinant Monoclonal Antibody | Getagozumab | hIgG1 |
| CSB-RA004929MA2HU | CD38 (Erzotabart) Recombinant Monoclonal Antibody | Erzotabart | hIgG1 |
| CSB-RA013263MA2HU | LYPD3 (Lupartumab) Recombinant Monoclonal Antibody | Lupartumab | hIgG1 |
| CSB-RA878862MA1HU | DLL4 (Navicixizumab) Recombinant Monoclonal Antibody | Navicixizumab | hIgG2 |
| CSB-RA023965MA2HU | DR5 (Conatumumab) Recombinant Monoclonal Antibody | Conatumumab | hIgG1 |
| CSB-RA56059MA1HU | MICA/B (CLN-619) Recombinant Monoclonal Antibody | CLN-619 | hIgG1 |
| CSB-RA019049MA2HU | CD45 (Apamistamab) Recombinant Monoclonal Antibody | Apamistamab | mIgG1 |
| CSB-RA017647MA2HU | PCSK9 (Alirocumab) Recombinant Monoclonal Antibody | Alirocumab | hIgG1 |
| CSB-RA011586MA1HU | IL12A (briakinumab) Recombinant Monoclonal Antibody | briakinumab | hIgG1 |
| CSB-RA819484MA1HU | LRRC15 (Samrotamab) Recombinant Monoclonal Antibody | Samrotamab | hIgG1 |
| CSB-RA005271MA1HU | CFD (lampalizumab) Recombinant Monoclonal Antibody | lampalizumab | hIgG1 |
| CSB-RA009316MA1HU | GCGR (crotedumab) Recombinant Monoclonal Antibody | crotedumab | hIgG1 |
| CSB-RA011087MA2HU | IGF1R (teprotumumab) Recombinant Monoclonal Antibody | teprotumumab | hIgG1 |
| CSB-RA16849MA1HU | IGHE (Ligelizumab) Recombinant Monoclonal Antibody | Ligelizumab | hIgG1 |
| CSB-RA004888MA5HU | CD19 (FMC63) Recombinant Monoclonal Antibody | FMC63 | scFv-his |
| CSB-RA007916MA1HU | F11 (Abelacimab) Recombinant Monoclonal Antibody | Abelacimab | hIgG1 |
| CSB-RA004935MA3HU | CD4 (Semzuvolimab) Recombinant Monoclonal Antibody | Semzuvolimab | hIgG1 |
| CSB-RA011050MA1HU | IFNG (mapalumab) Recombinant Monoclonal Antibody | mapalumab | hIgG1 |
| CSB-RA882142A1HU | DLL3 Recombinant Monoclonal Antibody | Rovalpituzumab | Human IgG1 |
| CSB-RA835707A1HU | SEMA4D Recombinant Monoclonal Antibody | US20220073608 | Human IgG4(S228P) |
| CSB-RA004847A1HU | CCR8 Recombinant Monoclonal Antibody | US20220064312A1 | Human IgG1 |